It was announced today that Chicago Growth Partners has acquired Caprion Proteomics, a provider of proteomic biomarkers, from Great Point Partners.
Caprion is a provider of proteomics services to pharmaceutical and biotechnology companies as well as government research institutions. Caprion’s key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development. The company is based in Montreal (www.caprion.com).
Harris Williams & Co. acted as an advisor to Caprion. The transaction closed on July 19, 2012 and was led by James Clark, Turner Bredrup, Geoff Smith, Whit Knier and Paul Hepper from the firm’s Healthcare & Life Sciences (HCLS) Group.
“Caprion has established itself as the market leader in providing outsourced proteomic biomarker discovery and immune monitoring services for its growing list of blue-chip pharmaceutical and biotechnology clients. Caprion is well positioned as the pharmaceutical industry continues to outsource critical elements of the drug development process to maximize returns on its research and development spend,” said James Clark, a managing director in Harris Williams & Co.’s HCLS Group.
Chicago Growth Partners invests from $15 million to $75 million of equity in companies with revenues from $15 million to $150 million. The firm targets three primary sectors: education; business and consumer services; healthcare products and services; and industrial growth. CGP is currently investing its second fund, Chicago Growth Partners II with $500 million of capital commitments. The firm is based in Chicago, IL (www.cgp.com).
Great Point Partners is a health care investment firm with approximately $450 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently the firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals and workers compensation. The firm is located in Greenwich, CT (www.gppfunds.com).